Follow GeneVentiv’s progress through company announcements and independent media coverage.
The latest news and announcements from GeneVentiv Therapeutics.
GeneVentiv announced a successful FDA INTERACT meeting for GENV-HEM and alignment on the program’s IND-enabling development plan and CMC strategy.
Read Release →GeneVentiv announced selection into the NHLBI Catalyze program to support IND-enabling toxicology work for GENV-HEM.
Read Release →GeneVentiv announced a global licensing agreement with Duke University for the technology underlying GENV-002.
Read Release →GeneVentiv announced that Sylvia Fong, Ph.D. joined the company’s Scientific Advisory Board.
Read Release →The companies announced a development and manufacturing collaboration supporting GENV-HEM.
Read Release →GeneVentiv announced plans to attend the BIO CEO & Investor Conference in New York.
Read Release →GeneVentiv announced plans to attend Biotech Showcase and BIO Partnering meetings during the J.P. Morgan Healthcare Conference period.
Read Release →GeneVentiv announced its participation in BIO-Europe Fall 2023.
Read Release →GeneVentiv announced plans to attend BIO Investor Forum in San Francisco.
Read Release →GeneVentiv announced that it won the Startup Spotlight pitch competition at BioPharm America 2023.
Read Release →GeneVentiv announced an invitation to present at BioPharm America 2023 in Raleigh.
Read Release →GeneVentiv announced the addition of Robert Baffi and Deborah Wild as advisors.
Read Release →GeneVentiv announced plans to attend BIO International 2023 in Boston.
Read Release →GeneVentiv announced an invitation to present as part of Labcorp’s symposium at the ASGCT annual meeting.
Read Release →GeneVentiv announced an invitation to present preclinical GENV-HEM data at the National Hemophilia Foundation workshop.
Read Release →GeneVentiv announced additions to its management team and board of directors.
Read Release →GeneVentiv announced a $250,000 Strategic Research Loan from the North Carolina Biotechnology Center.
Read Release →GeneVentiv announced FDA orphan drug designation for GENV-HEM. This historical release preserves the program positioning used at the time.
Read Release →GeneVentiv announced an expansion of its Scientific Advisory Board.
Read Release →GeneVentiv announced an appointment to its Scientific Advisory Board.
Read Release →GeneVentiv and the University of North Carolina at Chapel Hill announced a license agreement for the technology that became the company’s hemophilia program.
Read Release →GeneVentiv Therapeutics in the news and media.
Coverage of GeneVentiv’s scientific debut at ASGCT 2026.
Read coverage →Independent coverage of GeneVentiv’s FDA INTERACT meeting and development plans for GENV-HEM.
Read coverage →A profile of GeneVentiv’s origins, programs and development strategy in North Carolina’s gene therapy ecosystem.
Read coverage →Coverage of Duke University’s licensing of the Pompe disease gene-editing technology to GeneVentiv.
Read coverage →Coverage of GeneVentiv’s Direct-to-Phase II SBIR award supporting GENV-HEM development.
Read coverage →Coverage of the GeneVentiv and ReciBioPharm collaboration supporting GENV-HEM development.
Read coverage →An interview discussing GeneVentiv, GENV-HEM and the company’s development strategy.
Read coverage →Coverage of GeneVentiv financing to support its gene-therapy development work.
Read coverage →Coverage of early financing and development support for GeneVentiv.
Read coverage →Coverage of GeneVentiv’s Strategic Research Loan from the North Carolina Biotechnology Center.
Read coverage →Coverage of a KickStart Venture Services commercialization grant awarded to GeneVentiv.
Read coverage →Current hemophilia treatments have limitations for a significant number of patients.
Read coverage →A profile of GeneVentiv and its early hemophilia gene-therapy program.
Read coverage →Coverage of FDA orphan drug designation for GENV-HEM.
Read coverage →GeneVentiv was included among companies participating in CED’s Venture Connect 2021.
Read coverage →Early coverage of GeneVentiv’s formation around hemophilia gene-therapy technology from UNC-Chapel Hill.
Read coverage →Coverage of GeneVentiv’s launch and UNC-derived hemophilia gene-therapy program.
Read coverage →Coverage of the license agreement between GeneVentiv and UNC-Chapel Hill.
Read coverage →Historical GeneVentiv coverage announcing the UNC license and the company’s hemophilia gene-therapy program.
Read coverage →